Evidence map›Paper›PMID 36964555›Full record

ArticleJournal of translational medicine2023

Exploring the putative role of PRDM1 and PRDM2 transcripts as mediators of T lymphocyte activation.

Erika Di Zazzo, Monica Rienzo, Amelia Casamassimi, Caterina De Rosa, Nicola Medici, Patrizia Gazzerro, Maurizio Bifulco, Ciro Abbondanza

Open access · goldFull text read
In one paragraph

Article in Journal of translational medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Erika Di Zazzo *Department of Medicine and Health Sciences "V. Tiberio", University of Molise, 86100, Campobasso, Italy.
Monica Rienzo *Department of Environmental, Biological, and Pharmaceutical Sciences and Technologies, University of Campania "Luigi Vanvitelli", 81100, Caserta, Italy.
Amelia CasamassimiDepartment of Precision Medicine, University of Campania "Luigi Vanvitelli", 80138, Naples, Italy.
Caterina De RosaDepartment of Precision Medicine, University of Campania "Luigi Vanvitelli", 80138, Naples, Italy.
Nicola MediciDepartment of Precision Medicine, University of Campania "Luigi Vanvitelli", 80138, Naples, Italy.
Patrizia GazzerroDepartment of Pharmacy, University of Salerno, 84084, Salerno, Fisciano (SA), Italy.
Maurizio Bifulco *Department of Molecular Medicine and Medical Biotechnologies, University of Naples "Federico II", 80131, Naples, Italy.
Ciro Abbondanza *Department of Precision Medicine, University of Campania "Luigi Vanvitelli", 80138, Naples, Italy. ciro.abbondanza@unicampania.it.ORCID 0000-0001-5346-4835
University of Campania "Luigi Vanvitelli" · ITUniversity of Molise · ITUniversity of Naples Federico II · ITUniversity of Salerno · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundT cell activation and programming from their naïve/resting state, characterized by widespread modifications in chromatin accessibility triggering extensive changes in transcriptional programs, is orchestrated by several cytokines and transcription regulators. PRDM1 and PRDM2 encode for proteins with PR/SET and zinc finger domains that control several biological processes, including cell differentiation, through epigenetic regulation of gene expression. Different transcripts leading to main protein isoforms with (PR +) or without (PR-) the PR/SET domain have been described. Although many studies have established the critical PRDM1 role in hematopoietic cell differentiation, maintenance and/or function, the single transcript contribution has not been investigated before. Otherwise, very few evidence is currently available on PRDM2. Here, we aimed to analyze the role of PRDM1 and PRDM2 different transcripts as mediators of T lymphocyte activation.

methodsWe analyzed the transcription signature of the main variants from PRDM1 (BLIMP1a and BLIMP1b) and PRDM2 (RIZ1 and RIZ2) genes, in human T lymphocytes and Jurkat cells overexpressing PRDM2 cDNAs following activation through different signals.

resultsT lymphocyte activation induced an early increase of RIZ2 and RIZ1 followed by BLIMP1b increase and finally by BLIMP1a increase. The "first" and the "second" signals shifted the balance towards the PR- forms for both genes. Interestingly, the PI3K signaling pathway modulated the RIZ1/RIZ2 ratio in favor of RIZ1 while the balance versus RIZ2 was promoted by MAPK pathway. Cytokines mediating different Jak/Stat signaling pathways (third signal) early modulated the expression of PRDM1 and PRDM2 and the relationship of their different transcripts confirming the early increase of the PR- transcripts. Different responses of T cell subpopulations were also observed. Jurkat cells showed that the acute transient RIZ2 increase promoted the balancing of PRDM1 forms towards BLIMP1b. The stable forced expression of RIZ1 or RIZ2 induced a significant variation in the expression of key transcription factors involved in T lymphocyte differentiation. The BLIMP1a/b balance shifted in favor of BLIMP1a in RIZ1-overexpressing cells and of BLIMP1b in RIZ2-overexpressing cells.

conclusionsThis study provides the first characterization of PRDM2 in T-lymphocyte activation/differentiation and novel insights on PRDM1 and PRDM2 transcription regulation during initial activation phases.

Indexed as

Epigenesis, GeneticLymphocyte ActivationCytokinesDNA-Binding ProteinsHistone-Lysine N-MethyltransferaseHumansNuclear ProteinsPhosphatidylinositol 3-KinasesPositive Regulatory Domain I-Binding Factor 1Transcription FactorsCytokinesDNA-Binding ProteinsHistone-Lysine N-MethyltransferaseNuclear ProteinsPhosphatidylinositol 3-KinasesPositive Regulatory Domain I-Binding Factor 1PRDM1 protein, humanPRDM2 protein, humanTranscription FactorsPRDM1/BLIMP1PRDM2/RIZT lymphocyte activationT lymphocyte commitmentTranscription factorsTranscription regulation

Identifiers

PMID36964555
PMCPMC10039509
OpenAlexW4360826171

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read28
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.